Sr Manager, QA Operations

Qualifications Bachelors or Masters in life sciences, Biology, Biochemistry, Chemical Engineering, Biotechnology or other related major. 8+ years of pharmaceutical manufacturing and/or Quality Assurance experience, with at least 2 years experience in the field of cell/gene therapies preferred. Experience with cGMP manufacturing and GDP as well as global regulatory regulations and

requirements for biopharmaceutical products and ATMPs. Strong Project Management skills and ability to manage multiple projects simultaneously. Independently motivated, detail oriented and good problem-solving ability. Highly collaborative team player who fosters open communication and facilitates mutual understanding and cooperation between all stakeholders. Domestic and international travel required, approximately 10% (including travel to CDMOs and/or Suppliers and internal business meeting, as needed). Excellent verbal, written and presentation skills and effectively communicate with all levels of management. Ability to work in a matrix environment and build strong relationships by being transparent, reliable, and delivering on commitments. The national salary range for this position is from $160K to $180K USD annually. This salary range is an estimate of what we reasonably expect to pay for this position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for

bonus,

benefits, and participation in Company’s stock plan. Apply for this job Links Home Platform & Pipeline Patients Inside Kyverna Education & Events Investors Careers Contact About Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101), is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. FOLLOW US ON SOCIAL Privacy Policy (US) Privacy Policy (EU/UK) Designed by Elegant Themes | Powered by WordPress

A meeting lands on your calendar

If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.